# IRESSA™ In Combo With Xeloda™ in Advanced Colorectal Cancer Patients After 1st-Line Chemo Failure

> **NCT00242788** · PHASE1,PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 40 (—)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Gefitinib and capecitabine

## Key facts

- **NCT ID:** NCT00242788
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** —
- **Final completion:** 2005-11
- **Target enrollment:** 40 (—)
- **Last updated:** 2009-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00242788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00242788, "IRESSA™ In Combo With Xeloda™ in Advanced Colorectal Cancer Patients After 1st-Line Chemo Failure". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00242788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*